ZOMETA® Reduces Skeletal-Related Events From Bone Metastases In Renal Cell Carcinoma

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumor types

Page

1 2

ZOMETA^® effectively helps to protect patients with renal cell carcinoma from the threat of SREs

Efficacy of ZOMETA vs placebo in patients with advanced renal cell carcinoma²

ZOMETA® Reduction in Time to First SRE vs Placebo in Renal Cell Carcinoma

NR=not reached.

ZOMETA significantly extended time to first SRE vs placebo (median not reached vs 72 days, P=.006)²
ZOMETA reduced the percentage of patients who experienced an SRE by 50% vs placebo (P=.015)²

ZOMETA can delay and reduce SREs in patients with renal cell carcinoma and bone metastases²

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® effectively helps to protect patients with renal cell carcinoma from the threat of SREs

ZOMETA can delay and reduce SREs in patients with renal cell carcinoma and bone metastases2

ZOMETA^® effectively helps to protect patients with renal cell carcinoma from the threat of SREs

ZOMETA can delay and reduce SREs in patients with renal cell carcinoma and bone metastases²